

Bioventix plc
 (“Bioventix” or the “Company”)

Director/PDMR Shareholding

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for application in clinical diagnostics, was notified on 18 November 2016 of the following transactions in its ordinary shares of 5 pence each (“Ordinary Shares”):

<i>Director</i>	<i>Position</i>	<i>Ordinary Shares sold</i>	<i>Sale price per Ordinary Share</i>	<i>Ordinary Shares held subsequently</i>	<i>Percentage of issued share capital held subsequently</i>
Ian Nicholson and Persons Closely Associated	Non-Executive Chairman	4,000	1300p	23,000	0.45%
Peter Harrison and Persons Closely Associated	CEO	100,000	1300p	508,176	9.96%

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.	Details of the person discharging managerial responsibilities / person closely associated	
a)	Names	Ian Nicholson (Non-Executive Chairman) Catherine Nicholson (PCA of Ian Nicholson) Peter Harrison (CEO) Abigail Harrison (PCA of Peter Harrison)
2.	Reason for the Notification	
a)	Position/status	See 1(a) above, all are PDMR’s or PCA’s of PDMR’s
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	Bioventix plc
b)	LEI	n/a
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the Financial instrument, type of instrument	Ordinary shares of 5 pence (“Ordinary Shares”)

	Identification code	GB00B4QVDF07																
b)	Nature of the transaction	In each case, sale of Ordinary Shares																
c)	Price(s) and volume(s)	<p>Ian Nicholson:</p> <table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>1300 pence</td> <td>2,000</td> </tr> </tbody> </table> <p>Catherine Nicholson:</p> <table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>1300 pence</td> <td>2,000</td> </tr> </tbody> </table> <p>Peter Harrison:</p> <table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>1300 pence</td> <td>98,000</td> </tr> </tbody> </table> <p>Abigail Harrison:</p> <table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>1300 pence</td> <td>2,000</td> </tr> </tbody> </table>	Price(s)	Volume(s)	1300 pence	2,000	Price(s)	Volume(s)	1300 pence	2,000	Price(s)	Volume(s)	1300 pence	98,000	Price(s)	Volume(s)	1300 pence	2,000
Price(s)	Volume(s)																	
1300 pence	2,000																	
Price(s)	Volume(s)																	
1300 pence	2,000																	
Price(s)	Volume(s)																	
1300 pence	98,000																	
Price(s)	Volume(s)																	
1300 pence	2,000																	
d)	Aggregated information: <ul style="list-style-type: none"> • Aggregated volume • Price 	<ul style="list-style-type: none"> - Ian Nicholson: Sale of 2,000 Ordinary Shares at a price of 1300 pence per Ordinary Share - Catherine Nicholson: Sale of 2,000 Ordinary Shares at a price of 1300 pence per Ordinary Share - Peter Harrison Sale of 98,000 Ordinary Shares at a price of 1300 pence per Ordinary Share - Abigail Harrison: Sale of 2,000 Ordinary Shares at a price of 1300 pence per Ordinary Share 																
e)	Date of the transaction	18 November 2016																
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)																

For further information please contact:

Bioventix plc
Peter Harrison

Chief Executive Officer

Tel: 01252 728 001

finnCap Ltd

Geoff Nash/Simon Hicks

Stephen Norcross

Corporate Finance

Corporate Broking

Tel: 020 7220 0500**About Bioventix plc:**

Bioventix (www.bioventix.com) specialises in the development and commercial supply of high-affinity monoclonal antibodies with a primary focus on their application in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at Bioventix are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. Bioventix currently offers a portfolio of antibodies to customers for both commercial use and R&D purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. Bioventix currently supplies antibody products and services to the majority of multinational clinical diagnostics companies. Bioventix is based in Farnham, UK and its shares are traded on AIM under the symbol BVXP.